Liaoning cancer hospital

Shenyang 110042

1 studies enrolling now · 4 studies all time

What they study most

Gastric Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Cancer, HER2-positive Gastric Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Studies at this site

• Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma — Recruiting now
• Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer — Completed
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer — Running, not enrolling
• A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer — Completed